Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0

Article  CAS  Google Scholar 

Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13:4287. https://doi.org/10.3390/cancers13174287

Sapino A, Goia M, Recupero D, Marchio C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol 3:129. https://doi.org/10.3389/fonc.2013.00129

Article  PubMed  PubMed Central  Google Scholar 

Raghav KPS, Moasser MM (2022) Molecular pathways and mechanisms of HER2 in cancer therapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-0283

Article  PubMed  Google Scholar 

Dogan I, Aydin E, Khanmammadov N, Paksoy N, Saip P, Aydiner A (2023) Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression. Sci Rep 13:8779. https://doi.org/10.1038/s41598-023-35715-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17:33–48. https://doi.org/10.1038/s41571-019-0268-3

Article  CAS  PubMed  Google Scholar 

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–530. https://doi.org/10.1016/S1470-2045(19)30863-0

Article  CAS  PubMed  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610–621. https://doi.org/10.1056/NEJMoa1914510

Article  CAS  PubMed  Google Scholar 

Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T et al (2017) Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 18:743–754. https://doi.org/10.1016/S1470-2045(17)30313-3

Article  CAS  PubMed  Google Scholar 

Dogan I, Paksoy N, Ak N, Vatansever S, Saip P, Aydiner A (2023) Prognostic factors influencing progression-free survival in HER2-positive metastatic breast cancer patients who were treated with a combination of lapatinib and capecitabine. Eur J Breast Health 19:128–133. https://doi.org/10.4274/ejbh.galenos.2023.2022-12-4

Article  PubMed  PubMed Central  Google Scholar 

Daniels B, Kiely BE, Tang M, Houssami N, Lord SJ, Pearson SA (2021) Trastuzumab emtansine for HER2-positive metastatic breast cancer: outcomes from a whole-of-population Australian cohort. Breast 58:106–112. https://doi.org/10.1016/j.breast.2021.05.001

Article  PubMed  PubMed Central  Google Scholar 

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V et al (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401:105–117. https://doi.org/10.1016/S0140-6736(22)02420-5

Article  CAS  PubMed  Google Scholar 

Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F et al (2020) Treatment landscape and prognosis after treatment with trastuzumab emtansine. Geburtshilfe Frauenheilkd 80:1134–1142. https://doi.org/10.1055/a-1286-2917

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al (2023) Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773–1785. https://doi.org/10.1016/S0140-6736(23)00725-0

Article  CAS  PubMed  Google Scholar 

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743. https://doi.org/10.1056/NEJMoa064320

Article  CAS  PubMed  Google Scholar 

Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71. https://doi.org/10.1016/S1470-2045(12)70432-1

Article  CAS  PubMed  Google Scholar